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Recently, the development of rotaxane-based architectures for biological applications has
started to attract interest. In this short review, we summarize the main advances that have
been realized in this burgeoning area of research, including the design of squaraine-
rotaxane dyes for optical bioimaging applications, host-rotaxanes as cellular transport
agents, enzyme-responsive rotaxanes and mechanized mesoporous silica nanoparticles
coated with “nanovalves” as drug delivery systems.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r é s u m é
Recemment, le developpement de rotaxanes pour des applications biologiques a suscite un
intere^t grandissant. Dans cette mise au point, nous resumons les principaux progres qui
ont ete realises dans ce domaine, en decrivant successivement les rotaxanes encapsulant
des squaraines pour l'imagerie biologique, les rotaxanes ho^tes comme agents de transport
cellulaire, les rotaxanes enzymo-sensibles et les nanoparticules de silice mesoporeuse
reve^tues de « nanovalves » pour la delivrance de medicaments.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since Jean-Pierre Sauvage reported in 1983 the ﬁrst
templated synthesis of a [2]catenane [1], considerable
research efforts have been devoted to the development of
novel synthetic strategies allowing the efﬁcient prepara-
tion of interlocked molecular architectures [2e4]. Forty
years of investigations in this ﬁeld gave birth to a broad
collection of structurally diverse rotaxanes, catenanes and
knots exhibiting unique chemical properties. More(S. Papot).
ed by Elsevier Masson SAS.recently, the functional aspects of such interlocked systems
has become the subject of intense research to ﬁnd practical
applications of mechanically bonded molecules [5]. Within
this framework, rotaxanes have been widely studied as
potential electronic devices, materials, sensors and key
components for molecular motors and machines [6e13].
Furthermore, some rotaxane- and pseudorotaxane-based
devices have been designed to interact with biological
systems, especially for the delivery of bioactive compounds
or biomedical imaging. In this short review, we report the
advances that have been realized in this burgeoning area of
research over the past 15 years. Herein, we will summarize
successively the main advances made in the design ofThis is an open access article under the CC BY-NC-ND license (http://
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tions, host-rotaxanes as cellular transport agents, enzyme-
responsive rotaxanes and mechanized mesoporous silica
nanoparticles coated with “nanovalves” as drug delivery
systems.
2. Squaraine-rotaxane dyes for optical bioimaging
applications
Squaraines are a class of near-IR dyes with promising
photophysical properties for optical bioimaging applica-
tions [14]. However, their use as ﬂuorescent probes is
limited by their inherent chemical instability that results
from the attack of biological nucleophiles on the electron-
deﬁcient cyclobutene ring. Additionally, squaraines
readily form aggregates in water which quench ﬂuores-
cence. To circumvent these drawbacks, Smith et al. pro-
posed to encapsulate the cyclobutene core of the squaraine
dye as the thread component inside an interlocked rotax-
ane structure [15e17]. Thus, using the hydrogen bond
directed clipping reaction developed earlier by Leigh et al.
[18e20], they synthesized a range of squaraine-derived
rotaxanes such as 1 (Scheme 1) [21e22].
As expected, the encapsulating macrocycle inhibited
aggregation and greatly enhanced the stability of the
squaraine dye in various media, preventing nucleophilic
attack on the cyclobutene moiety. Therefore, when incu-
bated with bovine serum, rotaxane 1awas stable for many
weeks whereas the corresponding thread was degraded
over a few minutes [17].
Soon after, Smith et al. published a remarkable exten-
sion of this work where they compared the performance
advantages of rotaxane 1b over the commonly used sul-
fonated cyanine dye Cy-5 [23]. Rotaxane 1b includes
zinc(II)-dipicolyl-amine (Zn-DPA) stoppers that also play
the role of targeting ligands since Zn-DPA groups are
known to target the anionic surfaces of bacterial cells [24].
The high stability of 1b permitted real time ﬂuorescence-
imaging of Escherichia coli bacteria undergoing cell divi-
sion, which was not possible using probes based on Cy-5.
Futhermore, rotaxane 1b allowed optical imaging of
Staphylococcus aureus and E. coli bacteria in living nudeScheme 1. Squaraine-rotaxane dyes formice showing the great potential of squaraine-rotaxane
dyes as bioimaging agents.
The same group developed the highly innovative inter-
locked system 2 that may be suitable for many types of
molecular imaging and biotechnology applications
(Scheme 2) [25].
Rotaxane 2 that features an endoperoxide macrocycle
was easily prepared from 3 by oxidation of one anthracene
unit in the presence of air under irradiation with red light.
The synthesis of precursor 3 was achieved using the
“Clicked Capping” method reported earlier by Smith et al.
[26,27]. With this design, interlocked system 2 was very
stable and can be stored at 20 C during extremely long
periods without any degradation. However, upon warming
at 37 C, compound 2 underwent a unimolecular cyclo-
reversion reaction leading to the release of singlet oxygen
together with the emission of near-IR light. Thus, such a
thermally activated rotaxane-based dye possesses both
chemiluminescence and ﬂuorescence properties making
this interlocked molecular system particularly interesting
for optical imaging. The validity of this concept was eval-
uated in living mouse with 2-labelled microparticles [25].
The results obtained in this study demonstrated that
squaraine rotaxanes including an endoperoxidemacrocycle
can be used in vivo as dual-modality molecular imaging
probes.
3. Host-rotaxanes as cellular transport agents
In 2003, Smithrud et al. proposed the use of host-[2]
rotaxanes with the aim to create synthetic compounds
that mimic proteins ensuring the functions of cellular
transport agents [28]. For this purpose, they designed a
series of [2]rotaxanes 4 containing an arginine-derivatized
dibenzyl-24-crown-8 (DB24C8) and a number of host
blocking groups, allowing the encapsulation of various
guest molecules (Scheme 3) [29]. With this design, the
wheel can freely slide along the thread, therefore adjusting
its position to form the most stable conformation for the
recognition of a given guest [30]. Also, the nature of the
host blocking group can be easily modulated by the DCC-
rotaxane method developed by the same group [31].optical bioimaging applications.
Scheme 2. A squaraine-rotaxane dye for in vivo dual-modality molecular imaging.
Scheme 3. Host-rotaxanes as cellular transport agents.
N. Pairault et al. / C. R. Chimie 19 (2016) 103e112 105Rotaxanes 4a and 4b, including an aromatic cleft and a
cyclophane pocket, respectively, were studied for the de-
livery of peptides into cells (Scheme 3) [32,33]. Indeed,
while many bioactive peptides hold great promise as
therapeutic agents, their use in vivo is hampered by poor
bioavailability mainly due to their inability to pass through
cellular membranes. Investigations conducted with 4a
conﬁrmed the importance of conformational ﬂexibility in
the ability of host-[2]rotaxanes to bind guests and trans-
port peptides into cells. Thus, Smithrud et al. demonstrated
that pre-incubation of rotaxane 4a with COS-7 cells
signiﬁcantly increased the uptake of a ﬂuoresceinated
pentapeptide (AVWAL). Furthermore, since cellular uptake
was largely temperature- and ATP-independent, it was
suggested that the rotaxane-peptide non-covalent complex
passed through the cell membrane via a passivemechanism. More recently, the same authors developed an
analogue of 4a containing an oligo(ethylene glycol) chain
on the axle, thereby increasing the length of the latter [34].
Interestingly, this new host-[2]rotaxane delivered more
efﬁciently a range of ﬂuoresceinated peptides into ovarian
tumour cells than 4a which possesses a shorter axle.
In a comparative study, Smithrud et al. showed that the
ability of cyclophane-[2]rotaxane 4b to transport ﬂuores-
cein into COS-7 cells was substantially better than that of
the cleft-[2]rotaxane 4a [28]. Additionally, 4b transported
ﬂuorescein to a greater extent into the nucleus, whereas 4a
delivered the ﬂuorescent probe more uniformly
throughout a cell. As the cyclophane pocket appeared to be
beneﬁcial for cell transport, rotaxane 4bwas tested for the
intracellular delivery of peptides possessing awide range of
side chains (displaying apolar and polar groups either
N. Pairault et al. / C. R. Chimie 19 (2016) 103e112106negatively or positively charged). These experiments
demonstrated the utility of rotaxane 4b for the transport of
peptides of all polarity across cell membranes, highlighting
the versatility of this concept.
More recently, Smithrud et al. studied host-[2]rotaxanes
enabling the transfer of alkali and alkaline cations from
aqueous solutions into chloroform [35]. In this context,
they proposed the use of the crown ether host-rotaxanes 5
as novel bacterial ionophores (Scheme 4) [36]. The authors
hypothesized that rotaxanes 5 would increase the intra-
cellular concentration of metal ions such as Ca2þ and Mg2þ,
thereby inducing cell death through apoptosis. When
incubatedwith SKOV-3 ovarian cancer cells, host-rotaxanes
5a and 5bwere cytotoxic in the lowmicromolar range. The
cytotoxicity of rotaxanes increased with the concentration
of either Ca2þ or Mg2þ conﬁrming that 5a and 5b operated
as expected by enhancing the intracellular concentration of
these ions.
4. Enzyme-responsive rotaxanes
Besides their poor ability to cross cell membranes, many
bioactive peptides suffer from in vivo instability as a result
of rapid enzymatic degradation. For instance, Met-
enkephalin is a pentapeptide (YGGFM) with interesting
antiproliferative activities against several cancer cell lines
[37e39]. However, this compound cannot be used as an
anticancer drug since it is degraded in less than 5 min in
human plasma. With the aim to circumvent this drawback,
our group, in collaboration with those of Leigh and
Aucagne, proposed the concept of enzyme-responsive
rotaxane-based propeptides [40]. Within this framework,
a pilot study was conducted with the glycorotaxane
[41e44] 6 programmed for the selective delivery of Met-
enkephalin at the tumour site (Scheme 5). This mechani-
cally interlocked system was composed of a galactoside
trigger, a self-immolative stopper [45,46], a pentapeptide-
based axle and a benzylic amide macrocycle [18,47,48].
With this design, we hypothesized that the macrocycle
should play the role of a temporary molecular shield pro-
tecting the peptidic bonds of Met-enkephalin from degra-
dation by plasmatic peptidases. Thus, when incubated inScheme 4. Host-rotaxanes ahuman plasma containing peptidases responsible of Met-
enkephalin degradation, rotaxane 6 was perfectly stable
over several days. In contrast, the corresponding thread
was degraded with a half-life of 5 h under the same con-
ditions, therefore demonstrating that encapsulation of the
pentapeptide within the rotaxane structure 6 prevented its
peptidase-mediated hydrolysis in plasma. We also showed
that the active peptide can be readily released in the
presence of b-galactosidase, an enzyme that has been
successfully targeted [49] in tumour tissues via antibody-
directed enzyme prodrug therapy strategies (ADEPT
[50,51]). As illustrated in Scheme 5, activation of the
galactoside trigger led to the formation of an unstable
phenolate intermediate that underwent a 1,6-elimination
followed by a spontaneous decarboxylation, enabling the
disassembly of the mechanically interlocked components
and the subsequent liberation of the free bioactive
pentapeptide.
While our study conﬁrmed the potential of this
approach for the transport and delivery of peptides with
antitumour activity, rotaxane 6 exhibited poor aqueous
solubility. We then decided to pursue our investigations in
this ﬁeld with the galactosidase-responsive rotaxane pro-
peptides 7 composed of a novel self-immolative linker and
a triglycyl peptide encapsulated by a macrocycle bearing
two hydrophilic moieties (Scheme 6) [52]. The compounds
7a and 7b were easily prepared via post-functionalisation
of the same bis-azido rotaxane 7c using the well-known
CuAAC ‘click’ reaction. Under such circumstances, the
clickable precursor 7c appeared as a useful platform for
accessing a wide range of propeptides decorated for spe-
ciﬁc biological applications. As expected both rotaxanes 7a
and 7b were more soluble in aqueous media than the un-
decorated rotaxane analogue 7d. Interestingly, the intro-
duction of the two glucosylated tetra(ethylene glycol)
substituents (rotaxane 7b) afforded an excellent aqueous
solubility that was 50,000-fold higher than that of rotaxane
7d. Moreover, the presence of the bulky hydrophilic groups
on the macrocycle did not alter the recognition of the
galactoside trigger, as the activation of the rotaxane pro-
peptide 7b with b-galactosidase efﬁciently released the
parent tripeptide.s bacterial ionophores.
Scheme 5. Met-enkephalin rotaxane propeptide.
Scheme 6. Rotaxane-based propeptides.
N. Pairault et al. / C. R. Chimie 19 (2016) 103e112 107More recently, our group developed the biocompatible
[2]rotaxane 8 programmed for the intracellular delivery of
paclitaxel while preventing its premature liberation in
plasma (Scheme 7) [53]. To achieve such a task in an
autonomous manner, the interlocked molecular system 8
includes an enzymatic trigger, a self-immolative linker, a
self-opening macrocycle, a hydrophilic stopper and an
esterase-sensitive thread linked to the C20-OH position of
paclitaxel. In the blood stream, the macrocycle acts as a
molecular shield protecting the ester bond from plasmatic
esterase-mediated hydrolysis. However, in the presence of
b-galactosidase, the cleavage of the galactoside trigger
initiates the disassembly of the mechanically interlocked
components, leading ultimately to the liberation of the free
axle as illustrated in Scheme 7. Unmasked in this way, theC20-OH ester of paclitaxel becomes accessible to esterases
which can therefore induce the release of the drug. As the
activity b-galactosidase is mainly intracellular, the
decomposition of rotaxane 8 occurs exclusively within
living cells. Moreover, this interlocked functional system
exhibits an appreciable level of selectivity for cancer cells
overexpressing b-galactosidase which is of interest since
the selective killing of tumour cells represents one of the
main challenges of cancer chemotherapy.
5. Rotaxane- and pseudorotaxane-based ‘nanovalves’
In 2005, Stoddart and Zink were the ﬁrst to propose the
use of mechanically interlocked molecules as ‘nanovalves’
for mechanized silica nanoparticles [54]. Mesoporous silica
Scheme 7. An enzyme-responsive rotaxane with a self-opening macrocycle.
N. Pairault et al. / C. R. Chimie 19 (2016) 103e112108nanoparticles (MSNPs) possess the ability to encapsulate a
wide variety of organic molecules and can accumulate
passively in solid tumours (the enhanced permeability and
retention of macromolecules in solid tumours is known as
the EPR effect [55]). As a result, MSNPs have been consid-
ered as potential carriers for the delivery of therapeutic and
diagnostic agents [56,57]. By attaching either rotaxane or
pseudorotaxane architectures to the silica matrix, Stoddart
and Zink aimed to release host molecules in a stringently
controlled fashion using a mobile macrocycle as a valve. In
this approach, when the macrocycle is close to the surface
of the particle (valves ‘closed’), the guest molecules remain
trapped within the pores of silica. On the other hand, in
response to a speciﬁc stimulus, the macrocycle can move
away from the surface (valves ‘opened’), thereby allowing
the liberation of cargo molecules. Based on this principle,
several types of ‘nanovalves’ have been studied in order to
control the nanopore opening using various stimuli such as
light, oxidation/reduction, changes in pH, and enzymes
[51,58e66]. Until now, most of these functional systems
have been designed to operate exclusively under abiotic
conditions. However, a few remarkable examples of MSNPs
functionalized with ‘nanovalves’, capable of delivering
potent anticancer drugs autonomously within living
tumour cells in vitro and in vivo, have been recently re-
ported in the literature [67,68]. In this context, the ﬁrst
example is the pH-sensitive supramolecular ‘nanovalve’ 9
composed of an N-methylbenzimidazole stalk attached
covalently to the nanopore opening and encircled by a b-
cyclodextrin (Scheme 8) [69]. At pH 7.0, the resultingpseudorotaxane was highly stable and no cargo leakage
was observed, showing that the ‘nanovalves’ remained
closed under these conditions. In contrast, upon decreasing
the pH at 5.0, protonation of the benzimidazole induced the
disassembly of the interlocked components leading to the
liberation of doxorubicin. These results indicated that such
MSNPs should be stable in plasma (pH 7.2), while releasing
the active drug once inside acidic cellular compartments.
To verify this hypothesis, the MSNPs loaded with doxoru-
bicin were incubated with squamous carcinoma KB-31 cell
lines. These experiments revealed that MSNPs were efﬁ-
ciently taken up into the endosomal compartment where
doxorubicin was released under acidic conditions provok-
ing cell death.
Very recently, Zhao et al. studied a range of redox-
responsive ‘nanovalves’ comprising a disulﬁde bond link-
age that can be reduced in the presence of intracellular
reductive agents such as glutathione (GSH) (Scheme 9)
[70e72]. These ‘nanovalves’ were equipped with various
targeting ligands allowing the selective recognition of the
corresponding membrane receptors overexpressed at the
surface of cancer cells. In this approach, following recep-
toreligand interactions, the MSNPs are internalized via
receptor-mediated endocytosis [73]. Once inside the target
cancer cell, the GSH-triggered disulﬁde cleavage induces
the opening of the valves and the subsequent drug release.
Based on this principle, Zhao et al. designed MSNPs loaded
with doxorubicin and decorated with the pseudorotaxane
10 [71]. This latter included an adamantyl stalk and a lac-
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Scheme 8. pH-responsive ‘nanovalves’.
N. Pairault et al. / C. R. Chimie 19 (2016) 103e112 109capper to prevent drug leakage. The lactobionic acidmoiety
was employed as a targeting ligand to enter selectively
HepG2 liver cancer cells expressing the asialoglycoprotein
receptor (ASGP-R) [74]. The anticancer efﬁcacy of such
MSNPs was evaluated on tumour-bearing nude mice
in vivo. This study demonstrated that doxorubicin was
selectively delivered and released within ASPG-R-positive
cancer cells thereby inhibiting the tumour growth with
minimal side effects.
The same group developed the [2]rotaxane 11 as a redox-
responsive ‘nanovalve’ programmed for the selective de-
livery of doxorubicin inside cancer cells overexpressing the
folate receptor (FR) [72]. With this design the folate groups
anchored at the surface of MSNPs act as both the stoppers of
the rotaxane 11 and targeting ligands. The FR is indeed
overexpressed in several cancer types while it is mainly
undetectable in most normal tissues [75]. Thus, the FR rep-
resents a target of choice to improve the selectivity of cancer
chemotherapies [76e78]. Under physiological conditions, a
negligible quantity of doxorubicin leaked from the MSNPs,
showing a good capping efﬁciency of rotaxane 11 on the
nanoparticle surface. However, in the presence of GSH,
doxorubicin was released from MSNPs with a rate depend-
ing on the concentration of the reducing agent, indicating
that the ‘valves’ opening proceeded as illustrated in Scheme
9. The potential of this targeting strategy was conﬁrmed
in vivo during the treatment of a subcutaneous HeLaxenograft implanted in nudemice. In these experiments, the
therapeutic efﬁcacy of MSNPs coated with rotaxane 11 was
superior to that of the free drug, inhibiting the tumour
growth without inducing signiﬁcant side effects.
Zhao et al. also proposed the use of photothermal-
responsive rotaxane-functionalized MSNPs for the
controlled release of bioactive compounds in vivo [79]. For
this purpose, they attached at the surface of MSNPs the
rotaxane 12 in which the cyclodextrin ring was threaded
with an azobenzene axle ended by a stopper containing
two sulfonic groups, enhancing the aqueous solubility of
the whole delivery system (Scheme 10).
Upon exposure to visible light or heating, the cis-to-
trans isomerization of the azobenzene unit induces the
cyclodextrin to shuttle to the trans-azobenzene position,
thereby opening the mesopores. On the other hand, irra-
diation at 365 nm produces the trans-to-cis photo-
isomerization of the azobenzene that causes the
cyclodextrin to move back to the triazole/ethylene glycol
position, resulting in the blockage of the pores of the
MSNPs. Thus, the control of the movement of the cyclo-
dextrin along the thread allows both drug storage and
release. The validity of this concept was conﬁrmed in vivo
on zebraﬁsh models with curcumin-loaded MSNPs. Cur-
cumin, a naturally ﬂuorescent polyphenol, was indeed
efﬁciently released when optically transparent zebraﬁsh
larvae were treated with either visible light or heat.
Scheme 9. Redox-responsive ‘nanovalves’.
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Scheme 10. Photothermal-responsive ‘nanovalves’.
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The development of functional rotaxanes for biological
applications started to attract interest about ﬁfteen years
ago. While this ﬁeld of research has not reached maturity
yet, some stimulating advances have been achieved,
particularly in the design of newmolecular delivery devices
and probes. These systems possess unusual chemical
properties due to the presence of mechanical bonds within
their structures. Thus, by using the macrocycle of rotaxanes
as a molecular shield, some labile chemical moieties can be
protected from premature degradation in biological envi-
ronments. This feature of rotaxane architectures has
already demonstrated its usefulness in preventing nucleo-
philic attack on the cyclobutene core of squaraines and the
hydrolysis of peptides or ester bonds in plasma. It was also
possible to exploit the mobility of the macrocycle along the
thread to develop adaptable host systems allowing the
transport of various peptides through cell membranes.
Moreover, ‘nanovalves’ and prodrugs, with functionalities
based on the controlled disassembly of the mechanically
interlocked components, have emerged as innovative drug
delivery systems.
Future research directions should focus on the
improvement of the biocompatibility of rotaxane-based
architectures that usually suffer from poor water solubil-
ity. For this purpose, novel versatile synthetic methods
allowing the preparation of a wide variety of rotaxanes
under aqueous conditions would be extremely useful. Such
synthetic advances could lead to the emergence of new
families of interlocked systems that could operate invarious biological environments, while until now these
types of rotaxane-based molecular machines functioned
exclusively under abiotic conditions (i.e. artiﬁcial muscles
and processive enzymes, rotaxane catalysts…). Next gen-
erations of functional rotaxanes should also interact more
selectively with biological targets in order to compete with
non-interlocked molecular systems already developed for
similar applications. Within this framework, an important
step has been realized very recently by Zhao et al. who
developed the ﬁrst MSNPs coated with ‘nanovalves’
bearing targeting ligands that enabled the selective
recognition of malignant cells in vivo.
Although numerous advances still remain to be accom-
plished to evaluate the real potential of rotaxane-based ar-
chitectures for biological applications, the functional
systems presented in this short review highlight the
promise offered by these interlocked molecules. Further
developments in this areawill certainly permit to determine
whatever this class of compounds will be of practical use to
explore or manipulate biological systems in the near future.References
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